title: H-2 haplotype-dependent serum IL-12 production in tumor-bearing mice treated with various mycelial extracts.
abstract: IL-12 is considered to be one of the most important cytokines in anti-cancer therapy. We have demonstrated that substances derived from Basidiomycetes, such as active hexose-correlated compound (AHCC) and PSK induce the production of IL-12. In this study, the MHC dependency of IL-12 production induced by various mycelial extracts, PSK, AHCC and IL-X, was examined. During tumor-bearing, higher serum IL-12 levels were observed in H-2a and H-2b mice as compared to H-2d mice. Concerning the effect of genetic background of mice on response to mycelial extracts, AHCC administration enhanced the serum IL-12 level in H-2b mice but not in H-2d mice, while PSK administration increased the serum IL-12 level in H-2d mice but not in H-2b mice. IL-X, components derived from the same Basidiomycetes, also enhanced the serum IL-12 level in H-2b mice in the early stage of tumor like AHCC, and maintained serum IL-12 at a level higher than the normal value accompanying tumor growth, whereas AHCC did not restore the lowered serum IL-12 level accompanying tumor growth. These results showed that AHCC or IL-X is effective in a genetically Th1-dominant individual whereas PSK is effective in a genetically Th2-dominant individual or Th2-dominant status in advanced cancer patients. So we propose that the suitable combinations of various mycelial extracts may be effective methods of endogenous IL-12 induction for cancer patients of all stages, which is important as a cancer therapy that is relatively free from adverse reactions and which emphasizes the QOL in individual patients.
authors: Institute of Immunotherapy for Cancer, Kinki University Hospital, 377-2, Ohnohigashi, Osakasayama-city, Osaka 589-8511, Japan.
authors: Akikuni
authors: A
authors: Yagita
authors: Syoji
authors: S
authors: Maruyama
authors: Shinji
authors: S
authors: Wakasugi
authors: Yasushi
authors: Y
authors: Sukegawa
mesh_terms: D000230:Adenocarcinoma; D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000627:therapeutic use; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use*; D001487:Basidiomycota / Q000737:chemistry; D018827:Carcinoma, Lewis Lung; D003110:Colonic Neoplasms; D006183:H-2 Antigens / Q000276:immunology*; D006239:Haplotypes; D018664:Interleukin-12 / Q000097:blood*; D051379:Mice; D020297:Mice, Congenic; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D025282:Mycelium / Q000737:chemistry; D009374:Neoplasms, Experimental / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D010936:Plant Extracts / Q000737:chemistry / Q000627:therapeutic use*; D011509:Proteoglycans / Q000737:chemistry / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D006183:H-2 Antigens; D010936:Plant Extracts; D011509:Proteoglycans; D018664:Interleukin-12; C010770:polysaccharide-K